1:36
ASH highlights: groundbreaking results from the TEAMM trial
Martin Kaiser
1:09
Treating GvHD: current challenges and newly approved drugs
Katie Gatwood
1:43
The importance of pharmacist intervention in the treatment of GvHD with ruxolitinib and ibrutinib
Katie Gatwood
2:29
Ruxolitinib and ibrutinib: the future for GvHD treatment?
Katie Gatwood
3:05
We know that MRD is relevant, what next?
Bijal Shah
3:35
The role of MRD in ALL: what defines a complete response?
Bijal Shah
1:45
How should we utilizing molecular data to improve ALL treatment?
Bijal Shah
5:10
Future frontiers in AML: the five key therapy pillars & the future of trials
Naval Daver
4:26
Making an IMPACT in ALL therapy: how can cure rates be improved?
David Marks
0:51
Nelarabine as first-line treatment for T-cell ALL: facing the problem up-front
David Marks
1:26
Rituximab vs. standard chemotherapy: which treatment benefits B-cell ALL patients more?
David Marks
2:30
Is low-dose cytarabine being overlooked in combination therapies for elderly AML?
Jorge Cortes
9:08
iwAL 2018 day 2 discussion: novel approaches and targeted therapies in AML
Andrew Wei et al.
6:03
Genomics and acute leukemia management: artificial intelligence, deep learning & pre-leukemic clones
Ari Melnick et al.
8:13
Acute leukemias discussion: what does genomics and epigenomics tell us about patient management?
Ari Melnick et al.
11:57
The evolving genomic landscape of ALL: molecular genetics, profiling and classification
Anjali Advani et al.
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

The content of VJHemOnc is intended for healthcare professionals